The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Dear all, at some point not too far away, will start to see the rest of the SNG story unfold. As a new investor, I wanted to say thanks to all the people adding constructive and reasoned arguments and information (to either end of the spectrum) to help inform decision making. Having undertaken research and spent a lot of time reading the posts and links, this has been invaluable. Ultimately, I have made a my choices and have only myself to kick or praise, but there is somehow a comfort knowing I am not the only one doing the same, particularly at a time of social isolation and challenge. Genuinely best of luck to all and I hope that this company can play an important role in making the world better in its own way. If not, lots learned on the way! Thanks all.
might be of interest - some notes about results timings
https://www.trialsitenews.com/university-of-southampton-spinoff-venture-synairgen-expand-study-of-sng001-to-include-virtual-design-in-support-of-covid-19-patients/
Taken from the Preliminary Results RNS this morning
Outlook
"During the calendar year 2019 we made good progress in the trial of our wholly-owned asset SNG001 in COPD. The emergence of SARS-CoV-2 has caused us to pause the COPD trial and to divert our expertise and investment to addressing the more pressing COVID-19 pandemic. Knowing that a broad spectrum antiviral agent delivered directly to the lungs may prevent the development of lower respiratory tract illness or accelerate the recovery of patients already hospitalised, we have raised additional funding of £14 million, which has enabled us to successfully initiate a trial of approximately 220 patients with COVID-19, some 100 of whom are in the hospital environment with severe respiratory symptoms, with a further 120 patients who will be dosed in the home environment upon early signs of COVID-19. Our staff and our key suppliers in both the UK and overseas have been able to continue working through lockdown. Data from the hospital trial will read out during the summer, and, if positive, the Company will work closely with regulators to determine an expeditious route to securing approval for SNG001, a treatment we believe could play an important role in addressing the current COVID-19 crisis and similar viruses in the future. In parallel, the Company is now working with manufacturers to scale up for potential demand for SNG001. The outlook for the business is positive and we look forward to updating the market on further progress in due course."
I think this is a really positive position which looks not just to this outbreak but potentially others of a similar type in the future. I read this as a drug that could be well placed to provide relief in the interim period if a similar virus emerges and a vaccine takes time to develop or, in the worst case, cannot be developed. It also re-iterates the supply side and how that is already in hand. Mentions a release timing of data from the hospital trial but does not mention the home trial in this section. DYOR and GLA
Am I reading this right or wrong? I know AZ have a history with SNG but if you follow the link in Formul1187's helpful post of 0934, the AZ site has another link to the RECOVERY work on the NIHR site in the second to last para which takes you here https://www.nihr.ac.uk/covid-studies/study-detail.htm?entryId=281712
That talks about the RECOVERY work sponsored by Oxford UNI which refers to INF B1b - aren't SNG using INF B1a? Or am I now losing the plot? Thanks!
Currently recruiting to support their COVID related work - closing date for applications is tomorrow......
https://www.synairgen.com/contact-us/employment-opportunities/
might be of interest - Synairgen feature in the list
https://post.parliament.uk/analysis/covid-19-therapies/
apols - not sure what happened there - try this - it's in the articles listed
https://scitechdaily.com/news/health/
another report of the same study:
https://scitechdaily.com/study-shows-treatment-with-interferon-a2b-speeds-up-recovery-of-covid-19-patients/
Hi all,
new to the Board and first post so trying to research and add to the info gathered. Update on the HRA page (last updated today) listing the trial. Apols if already known, old news and discussed but couldn't see it - am I right in thinking that the trial has been amended (approval given on 22/04/2020) for: (pasted from HRA page)
The addition of a point-of-care viral infection test;
Testing for confirmation of COVID-19 is currently being done at hospital laboratories and results are taking 24-36 hours to come through. We are finding that patients often have had COVID-19 symptoms for an average of 7-10 days by the time they are admitted to hospital. Ideally we would like patients to receive the first dose of study medication as early as possible into their illness to give it it’s best chance of working and to stop the further spread of the virus, therefore waiting for a further 24-36 hours after the patient is admitted to find out the hospital laboratory results is not ideal.
We have sourced a point-of-care test, that can be done at the hospital bedside and gives results within 10-15 minutes. The point-of-care test we plan to use will confirm the presence of a viral infection, if after clinical assessment there is also a strong clinical suspicion that the patent has COVID-19 the patient will enter the study rather than wait for the hospital laboratory result.
The addition of this testing will help with recruitment into the study and also ensure we are able to give the study medication as quickly as possible.
The method of informed consent;
Originally the protocol stated that written informed consent should be taken. However, as we have moved forwards with the study, due to the isolation precautions the hospitals are having to take, some of our sites have said that they will need to take informed consent using different methods. These methods are approved by the sponsor prior to the site implementing them. The protocol has been adapted to allow for verbal and electronic consent to be taken. It is thought that for the Pilot phase of the study i.e. the first 100 randomised patients, that written and verbal consent will be the methods used. Electronic consent has also been added to future proof the protocol if needed.